Roche has entered a $250 million deal to acquire an immuno-oncology program from Good Therapeutics, a Seattle-based biotech. The deal is anticipated to close in the third quarter of 2022, and will give Roche full rights to Good’s PD1-regulated IL-2 receptor agonist program. “[The program] nicely complements our efforts on next-generation PD-1-targeted IL-2 therapeutics and our broader oncology strategy of providing cancer patients with innovative solutions and improving health outcomes,” James Sabry, Roche’s global head of pharma partnering, said in a news release. Roche’s existing PD-L1 therapy, Tecentriq, is a blockbuster, bringing in $3.63 billion in global sales as the French drugmaker’s no. 3 bestselling drug. Evaluate Pharma projects it will be Roche’s no. 2 bestseller by 2023, reaching $4.93 billion in global sales.